Health Technology · Pharmaceuticals: Major · NSE: NGLFINE · data 2026-10-09
NGL Fine-Chem Ltd.
Health check: Strong (8.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,925
Market cap
₹1,845 cr
P/E
31.6
P/B
—
ROE
15.7%
ROCE
17.1%
Debt / equity
0.37
Dividend yield
0.06%
1-year return
95.7%
52-week high
₹3,602
52-week low
₹1,271
Operating margin
11.9%
Growth
| Revenue (last 12 months) | ₹536 cr |
| Net profit (last 12 months) | ₹57 cr |
| Sales growth, 3 years (yearly) | 21.7% |
| Profit growth, 3 years (yearly) | 32.9% |
Similar companies
Indoco Remedies Limited (INDOCO) · Panacea Biotec Limited (PANACEABIO) · Beta Drugs Ltd. (BETA) · Windlas Biotech Ltd. (WINDLAS) · Hester Biosciences Limited (HESTERBIO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NGLFINE in NSE Scanner →